Efficacy and Safety of Abicipar in Neovascular Age-Related Macular Degeneration

Derek Y Kunimoto; Young Hee Yoon; Charles C. Wykoff; Andrew Chang; Rahul N. Khurana; Raj K. Maturi; Hansjürgen Agostini; Eric H Souied; David R. Chow; Andrew J. Lotery; Cedar; Sequoia Study Groups

doi:https://doi.org/10.1016/j.ophtha.2020.03.035

doi.org/10.1016/j.ophtha.2020.03.035

Efficacy and Safety of Abicipar in Neovascular Age-Related Macular Degeneration

,

,

..., Sequoia Study Groups

2

Ophthalmology

Volume: 127, Issue: 10, Pages: 1331 - 1344

Published: Oct 1, 2020

Abstract

PurposeTo compare the efficacy and safety of abicipar every 8 weeks and quarterly (after initial doses) versus ranibizumab every 4 weeks in treatment-naïve patients with neovascular age-related macular degeneration (AMD).DesignTwo randomized, multicenter, double-masked, parallel-group, active-controlled, phase 3 clinical trials (CEDAR, SEQUOIA) with identical protocols were conducted. Data from both trials were pooled for...

Paper Fields

Paper Details

Title

Efficacy and Safety of Abicipar in Neovascular Age-Related Macular Degeneration

DOI

doi.org/10.1016/j.ophtha.2020.03.035

Published Date

Oct 1, 2020

Journal

Ophthalmology

Volume

127

Issue

10

Pages

1331 - 1344

Citation AnalysisPro

You’ll need to upgrade your plan to Pro

Looking to understand the true influence of a researcher’s work across journals & affiliations?

Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.

Learn more

Notes

History